Category Press Releases

Huonslab Earns Formulation Patent for HYDIZYME™, Its Recombinant Human Hyaluronidase Product

Huonslab Strengthens HYDIZYME™ Pipeline with Formulation Patent, Targeting 2026 Market Launch Huonslab Co., Ltd., a subsidiary of Huons Global (KOSDAQ:084110), has taken a major step forward in its mission to bring innovative biologic formulations to market with the announcement that…

Read MoreHuonslab Earns Formulation Patent for HYDIZYME™, Its Recombinant Human Hyaluronidase Product

Charles River Collaborates with Elly to Advance Gene Therapies for Rare Diseases

Charles River Teams Up with Elly’s Team to Accelerate Gene Therapy for Ultra-Rare NEDAMSS Disorder Charles River Laboratories International, Inc. (NYSE: CRL), a global leader in early-stage drug development and manufacturing services, has announced a collaborative agreement with Elly’s Team,…

Read MoreCharles River Collaborates with Elly to Advance Gene Therapies for Rare Diseases

Bristol Myers’ sNDA for Sotyktu in Psoriatic Arthritis Accepted in Four Global Regions

Bristol Myers Squibb’s Sotyktu Makes Global Regulatory Progress for Psoriatic Arthritis as FDA Accepts sNDA for Review In a major development for immunology-focused therapeutics, Bristol Myers Squibb (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) has…

Read MoreBristol Myers’ sNDA for Sotyktu in Psoriatic Arthritis Accepted in Four Global Regions

Fresenius Kabi Honored with 2025 Premier Supplier Legacy Award for Longstanding Excellence

Fresenius Kabi Honored with 2025 Premier Supplier Legacy Award for Continued Excellence in Healthcare Delivery Fresenius Kabi, a leading global healthcare company specializing in lifesaving medicines and technologies, has once again been recognized for its longstanding commitment to excellence in…

Read MoreFresenius Kabi Honored with 2025 Premier Supplier Legacy Award for Longstanding Excellence

Tempus Secures FDA 510(k) Clearance for AI-Powered ECG-Low EF Diagnostic Software

Tempus Secures FDA 510(k) Clearance for AI-Driven ECG-Low EF Software, Expanding Capabilities in Cardiovascular Risk Detection Tempus AI, Inc. (NASDAQ: TEM), a trailblazer in applying artificial intelligence to drive precision medicine forward, has reached a significant milestone in the cardiology…

Read MoreTempus Secures FDA 510(k) Clearance for AI-Powered ECG-Low EF Diagnostic Software

Satellos Names Dr. Wildon Farwell as Chief Medical Officer to Lead Clinical Strategy

Satellos Bioscience Names Renowned Neuromuscular Expert Dr. Wildon Farwell as Chief Medical Officer to Advance Duchenne Therapy Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), a biotechnology company pioneering small molecule therapies to treat muscle diseases, has appointed Dr. Wildon Farwell,…

Read MoreSatellos Names Dr. Wildon Farwell as Chief Medical Officer to Lead Clinical Strategy